MYCN is amplified in some forms of neuroblastoma and prostate cancers and predicts poor prognosis [16,17]; therefore, inhibition of AURKA–MYCN binding might also be a useful therapeutic approach in these cancers [13,18,19]. This evidence concerns the gene MYCN and Familial prostate cancer.